STAT3 and lung carcinoma: The current work sought to provide novel insights into the functional response of MALAT1 and efficacy of common members of SLs (ALT and Brv-A) in paclitaxel-resistant lung cancer, vis-à-vis MALAT1/STAT3 and MALAT1/FUT4 axis.